Cargando…

Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.

Lung tumours of non small cell pathology were cultured by clonogenic assay in several media. Culture was successful in spleen conditioned medium, but only 57% grew and low plating efficiencies (PE) meant that only 23% of the original number produced significant drug results. Comparison of rat erythr...

Descripción completa

Detalles Bibliográficos
Autores principales: Simmonds, A. P., Hamilton, P. S., Kerr, H., Harvey, K., Moyes, P., Davidson, K. G., Faichney, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001492/
https://www.ncbi.nlm.nih.gov/pubmed/3022779
_version_ 1782135615593119744
author Simmonds, A. P.
Hamilton, P. S.
Kerr, H.
Harvey, K.
Moyes, P.
Davidson, K. G.
Faichney, A.
author_facet Simmonds, A. P.
Hamilton, P. S.
Kerr, H.
Harvey, K.
Moyes, P.
Davidson, K. G.
Faichney, A.
author_sort Simmonds, A. P.
collection PubMed
description Lung tumours of non small cell pathology were cultured by clonogenic assay in several media. Culture was successful in spleen conditioned medium, but only 57% grew and low plating efficiencies (PE) meant that only 23% of the original number produced significant drug results. Comparison of rat erythrocyte lysate (REL) medium with serum free defined medium (HITES) and HITES + 10% FBS demonstrated clear enhancement of PE in REL although growth was 100% successful in all these media. Ninety-three percent of samples tested against drugs in REL produced significant results. A later comparison of REL with McCoy's 5A + rbc +/- hydrocortisone produced relatively poor culture success for these 3 media and equivocal growth patterns. Low PE was attributed to age of rats used for rbc. Vindesine and cis-platinum cytotoxicity in spleen conditioned medium were 61% and 15% sensitivity respectively. These do not concur with clinical experience but the figures for overt resistance, at 39% and 69%, correspond with expected non-responders to these regimes. Drug testing in REL produced figures correlating more closely with clinical performance at 45% sensitivity to platinum and 36% of patients sensitive to both drugs, but the vindesine sensitivity at 55% is again discrepant with performance of this drug as a single agent.
format Text
id pubmed-2001492
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20014922009-09-10 Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media. Simmonds, A. P. Hamilton, P. S. Kerr, H. Harvey, K. Moyes, P. Davidson, K. G. Faichney, A. Br J Cancer Research Article Lung tumours of non small cell pathology were cultured by clonogenic assay in several media. Culture was successful in spleen conditioned medium, but only 57% grew and low plating efficiencies (PE) meant that only 23% of the original number produced significant drug results. Comparison of rat erythrocyte lysate (REL) medium with serum free defined medium (HITES) and HITES + 10% FBS demonstrated clear enhancement of PE in REL although growth was 100% successful in all these media. Ninety-three percent of samples tested against drugs in REL produced significant results. A later comparison of REL with McCoy's 5A + rbc +/- hydrocortisone produced relatively poor culture success for these 3 media and equivocal growth patterns. Low PE was attributed to age of rats used for rbc. Vindesine and cis-platinum cytotoxicity in spleen conditioned medium were 61% and 15% sensitivity respectively. These do not concur with clinical experience but the figures for overt resistance, at 39% and 69%, correspond with expected non-responders to these regimes. Drug testing in REL produced figures correlating more closely with clinical performance at 45% sensitivity to platinum and 36% of patients sensitive to both drugs, but the vindesine sensitivity at 55% is again discrepant with performance of this drug as a single agent. Nature Publishing Group 1986-10 /pmc/articles/PMC2001492/ /pubmed/3022779 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Simmonds, A. P.
Hamilton, P. S.
Kerr, H.
Harvey, K.
Moyes, P.
Davidson, K. G.
Faichney, A.
Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.
title Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.
title_full Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.
title_fullStr Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.
title_full_unstemmed Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.
title_short Drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.
title_sort drug sensitivity of non small cell carcinoma of lung by clonogenic assay in several media.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001492/
https://www.ncbi.nlm.nih.gov/pubmed/3022779
work_keys_str_mv AT simmondsap drugsensitivityofnonsmallcellcarcinomaoflungbyclonogenicassayinseveralmedia
AT hamiltonps drugsensitivityofnonsmallcellcarcinomaoflungbyclonogenicassayinseveralmedia
AT kerrh drugsensitivityofnonsmallcellcarcinomaoflungbyclonogenicassayinseveralmedia
AT harveyk drugsensitivityofnonsmallcellcarcinomaoflungbyclonogenicassayinseveralmedia
AT moyesp drugsensitivityofnonsmallcellcarcinomaoflungbyclonogenicassayinseveralmedia
AT davidsonkg drugsensitivityofnonsmallcellcarcinomaoflungbyclonogenicassayinseveralmedia
AT faichneya drugsensitivityofnonsmallcellcarcinomaoflungbyclonogenicassayinseveralmedia